Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | STK4 | Q13043 | 1/20 | 0.30 |
| ▸ | STK3 | Q13188 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339138 | 0.75 | KDM4E (0.48) | PIM1PIM3PIM2HSD11B1 | |
| SCHEMBL1338652 | 0.75 | ATM (0.47) | RIPK2NOD2HSD11B1MAPK14THRB | |
| SCHEMBL1339276 | 0.73 | MKNK1 (0.43) | HSD11B1MAPK14 | |
| SCHEMBL1339432 | 0.73 | CNR1 (0.40) | HSD11B1MAPK14 | |
| SCHEMBL1338076 | 0.72 | CNR1 (0.40) | RIPK2NOD2CD38HSD11B1MAPK14 | |
| SCHEMBL1338674 | 0.71 | F2RL3 (0.37) | HSD11B1MAPK14STK4STK3SIK2 | |
| SCHEMBL1338634 | 0.71 | PTPN1 (0.36) | RIPK2NOD2HSD11B1MAPK14THRB | |
| SCHEMBL1339284 | 0.70 | EIF4E (0.37) | HSD11B1MAPK14STK4STK3SIK2 | |
| SCHEMBL1338829 | 0.70 | ALDH1A1 (0.47) | CD38MAPK14 | |
| SCHEMBL1338617 | 0.70 | KDR (0.39) | RIPK2NOD2HSD11B1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063061-B2 | 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | claimed |
| EP-1940840-B1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-21 | — | — | EP | claimed |
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | claimed |
| EP-1940840-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | claimed |
| WO-2007045758-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-04-26 | — | — | WO | claimed |
| US-8063061-B2 | 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | disclosed |
| EP-1940840-B1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-21 | — | — | EP | disclosed |
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1940840-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045758-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | CYP11B2, CYP11B1, CYP2D6 | CLK1 3064/4885RIPK2 2972/4885NOD2 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.